F13A1 (Coagulation Factor XIII A Chain)

This is the first reported case of sclerosing epithelioid dermatofibroma exhibiting diffuse cytokeratin and p40/p63 expression. Recognizing this atypical immunophenotype is crucial to avoid diagnostic pitfalls, as it may mimic malignant epithelial or mesenchymal neoplasms such as sarcomatoid squamous cell carcinoma or epithelioid sarcoma. The expression likely reflects phenotypic plasticity rather than true epithelial malignancy.

The three-protein panel demonstrates strong internal validation performance; however, these estimates may be optimistic due to feature selection performed prior to cross-validation. External validation in independent cohorts-including chronic pancreatitis controls and parallel CA19-9 assessment-will be essential to determine clinical applicability.

While the classic hepatosplenic and hematopoietic manifestation have been well described, APH manifesting in the head and neck is a distinct phenomenon that has only been reported on rare occasions. We provide a review of the literature of all cases of ALK positive histiocytosis affecting the head and neck to provide an overview of the clinicopathologic features as well as the molecular findings of this rare entity.

Combined with ultrasound, AMINP achieved highly efficient tumor enrichment, increasing active drug concentration 52.1-fold versus controls and achieving 98.9% tumor suppression, with no recurrence observed in rechallenge experiments. This system establishes a robust and promising method for precision drug delivery.

Importantly, this work moves beyond static baseline markers by emphasizing dynamic, pathway-level changes and provides a hypothesis-generating framework for longitudinal therapeutic monitoring. Candidate proteins such as tetranectin and coagulation factor XIII A chain are proposed as molecular features associated with treatment response, warranting further validation in larger, prospective cohorts before translational application.

Five potential diagnostic biomarkers for AS-MCL1, F13A1, RGS2, TLR8, and TAGAP-were identified. In addition, the m5C regulator NSUN3 plays a critical role in macrophage function, providing experimental evidence that may support the diagnosis and treatment of AS.

A targeted literature review confirmed the rarity of halos around dermatofibromas, which are typically eczematous. Our case expands the clinicopathologic spectrum to include a hypopigmented, non-eczematous Meyerson-like ("forme-fruste") halo variant and supports a dermoscopy-first approach to avoid over-triage to melanoma and help streamline care.

In conclusion, our case highlights that the primary diagnostic clue for ECD may be a single yellowish plaque, which requires further investigation in relation to other systemic symptoms. Vemurafenib treatment may lead to regression of systemic symptoms and cutaneous yellowish plaques associated with ECD carrying a BRAF mutation.

S100, SOX10, neurofilament and desmin are typically negative. While perineuriomas behave in a benign fashion, complete surgical excision is recommended.

This case report highlights the AS SS-OCT and IVCM findings in a rare example of COST. Histopathology and immunohistochemistry findings still remain the gold standard for diagnosis.

This report demonstrates an often overlooked association between delayed UCS and UR and suggests abdominal ultrasound if necessary for diagnosis.

Transcriptomic analysis confirmed the dominance of the COL1A1::PDGFB fusion transcript and revealed enrichment of pathways related to cancer, viral infection, and neuroactive ligand-receptor interaction. This novel imatinib-resistant DFSP cell line, DFSP-DPH1 provides a valuable preclinical model for investigating the molecular mechanisms underlying DFSP pathogenesis, drug resistance, and tumor progression, and for developing and evaluating novel therapeutic strategies.